A 52-year-old man undergoing interscalene block for shoulder surgery receives 20 mL of 0.75% ropivacaine. After 3 minutes, he develops tinnitus, visual disturbances, and tremors. Which feature would best differentiate early CNS toxicity from systemic toxicity involving the cardiovascular system?

Explanation

## Temporal Sequence and Discriminating Features of Local Anesthetic Toxicity **Key Point:** The **temporal sequence of symptom onset** is the best clinical discriminator between CNS-predominant and cardiac toxicity. CNS toxicity follows a predictable progression: prodromal symptoms → seizures → recovery (or cardiovascular involvement if severe). ### Progressive Phases of Local Anesthetic Toxicity ```mermaid flowchart TD A[Intravascular injection of LA]:::action --> B[CNS Phase 1: Excitation]:::outcome B --> C[Tinnitus, visual disturbances, tremors, restlessness]:::outcome C --> D{Dose continues to accumulate?}:::decision D -->|No| E[Symptoms resolve]:::outcome D -->|Yes| F[CNS Phase 2: Depression]:::outcome F --> G[Seizures, loss of consciousness]:::outcome G --> H{Severe toxicity?}:::decision H -->|Mild-moderate| I[Recovery with supportive care]:::outcome H -->|Severe/Cardiac involvement| J[Cardiovascular collapse]:::urgent J --> K[Bradycardia, hypotension, arrhythmias, VF]:::urgent ``` ### Comparison: CNS vs Cardiac Toxicity Presentation | Phase | CNS-Predominant (Lidocaine, Ropivacaine) | Cardiac-Predominant (Bupivacaine) | | --- | --- | --- | | **Prodrome** | Tinnitus, visual changes, tremor, restlessness | May be absent or minimal | | **Seizure onset** | Early (after prodrome) | Late or absent | | **Cardiovascular signs** | Hypertension, tachycardia initially | Bradycardia, hypotension early | | **Sequence** | CNS → Cardiac (if severe) | Cardiac ± CNS | | **Recovery** | Rapid with airway management | Prolonged, refractory | **High-Yield:** In the clinical vignette, the patient has **tinnitus, visual disturbances, and tremors** — these are **Phase 1 CNS excitation symptoms**. The presence of these prodromal symptoms **before seizures** indicates CNS-predominant toxicity. If seizures then occur, this confirms the CNS phase progression. **Clinical Pearl:** The sequence matters: - **Prodrome → Seizure → Recovery** = CNS-predominant (ropivacaine, lidocaine) - **Bradycardia/hypotension → VF** = Cardiac-predominant (bupivacaine) **Mnemonic:** **EXCITATION then DEPRESSION** — CNS toxicity follows this order. **Excitation** = tinnitus, tremor, restlessness. **Depression** = seizures, coma. Cardiac toxicity skips the excitation phase. **Warning:** Do not assume that because a patient has tremors and tinnitus, they will not progress to seizures. These are **early warning signs** — the patient is in Phase 1 and may progress to Phase 2 (seizures) if the dose continues to accumulate. [cite:Butterworth JF et al. Morgan and Mikhail's Clinical Anesthesiology. 6th ed. Ch 10; Covino BG. Toxicity of Local Anesthetics. In: Cousins MJ, Bridenbaugh PO, eds. Neural Blockade. 3rd ed.]